VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Imovax Rabies
Vaccine Information
  • Product Name: Rabies Vaccine
  • Tradename: Imovax
  • Manufacturer: Sanofi Pasteur, SA
  • Vaccine Ontology ID: VO_0000063
  • CDC CVX code: 18
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1724)
  • Host Species for Licensed Use: Human
  • Antigen: Strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA.
  • Preparation: The virus strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA, is harvested from infected human diploid cells (MRC-5 strain), concentrated by ultrafiltration and is inactivated by beta-propiolactone. One dose of reconstituted vaccine contains less than 100 mg albumin, less than 150 μg neomycin sulfate and 20 μg of phenol red indicator. The vaccine contains no preservative or stabilizer (FDA: Imovax).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: The vaccine should be stored in the refrigerator at 2°C to 8°C (35°F to 46°F). Do not freeze (FDA: Imovax).
  • Approved Age for Licensed Use: all ages
  • Contraindication: For postexposure treatment, there are no known specific contraindications to the use of IMOVAX Vaccine. In cases of pre-exposure immunization, there are no known specific contraindications other than situations such as developing febrile illness etc (FDA: Imovax).
  • Description: Imovax is a sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA. This vaccine must only be used intramuscularly and as a single dose vial (FDA: Imovax).
Host Response

Human Response

  • Immune Response: Seroconversion was often obtained with only one dose. With two doses one month apart, 100% of the recipients developed specific antibody (FDA: Imovax).
  • Side Effects: Most common side effects reported in clinical studies included: injection site reactions, headache, nausea, abdominal pain, muscle aches and dizziness (FDA: Imovax).
References
FDA: Imovax: FDA: Imovax vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm180097.htm]